¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"signal loss"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • functional hearing loss
    ±â´É³­Ã»
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
  • heat loss
    ¿­¼Õ½Ç
  • ionization loss
    ÀÌ¿ÂÈ­¼Õ½Ç
  • idiopathic sudden hearing loss
    Ư¹ßµ¹¹ß³­Ã», Ư¹ß°©ÀÛ³­Ã»
  • insensible loss
    ºÒ°¨»ó½Ç
  • loss
    »ó½Ç, ¼Õ½Ç, ¼Ò½Ç
  • loss-of-function mutation
    ±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
  • mixed hearing loss
    È¥ÇÕ³­Ã»
  • neonatal hair loss
    ½Å»ý¾ÆÅ»¸ð
  • noise induced hearing loss
    ¼ÒÀ½³­Ã»
  • occupational hearing loss
    Á÷¾÷³­Ã»
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • condensed milk conductive hearing loss
    ³óÃà¿ìÀ¯ÀüµµÃ»°¢¼Ò½Ç
  • conductive hearing loss
    Àüµµ³­Ã»
  • conductive hearing loss
    ÀüÀ½¼º³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • functional hearing loss
    ±â´É³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç
  • heat loss
    ¿­¼Õ½Ç
  • idiopathic sudden hearing loss
    Ư¹ßµ¹¹ß³­Ã», Ư¹ß°©ÀÛ³­Ã»
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heat loss
    ¿­¼Õ½Ç(ËçËÛËà).
  • heating loss
    °¡¿­°¨·®(¡­ÊõåÖ).
  • idiopathic sudden hearing loss
    Ư¹ß¼º µ¹¹ß(¼º)³­Ã»
  • insensible loss
    ºÒ°¨»ó½Ç(¡­ßÃã÷).
  • insensible water loss
    ºÒ°¨¼º(ÝÕÊïàõ) ¼öºÐ»ó½Ç(â©ÝÂßÃã÷).
  • radiation loss
    ¹æ»ç¼±¼Õ½Ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • signal oversampling
    ½ÅÈ£ °ú ÃßÃâ
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • signal sequence
    ½ÅÈ£¼­¿­
  • signal stimuli
    ½ÅÈ£ÀÚ±Ø(ãáûÜô§Ð½).
  • signal symptom
    °æ°íÁõ»ó(ÌíͱñøßÒ)
  • signal to noise ratio (SNR)
    ½ÅÈ£ ´ë ÀâÀ½ºñ
  • signal transduction
    ½ÅÈ£Àü´Þ
  • signal transduction
    ½ÅȣƮ¶õ½º´ö¼Ç(ãáûÜ¡­), ½ÅÈ£ÇüÁúµµÀÔ(¡­û¡òõÓôìý)
  • signal void
    ¹«½ÅÈ£, ½ÅÈ£ ¼Ò½Ç, ½ÅÈ£ °øÇã
  • termination signal
    Á¾·á(ðûèç)½ÅÈ£.
  • tolerogenic signal
    °ü¿ëÀ¯¹ß½ÅÈ£ (¸é¿ª)
  • vascular signal void
    Ç÷°ü ½ÅÈ£¼Ò½Ç, Ç÷°ü ¹«½ÅÈ£
  • abrasion loss
    ¸¶¸ê·®(¸¶¸ê¾ç).
  • audiometric hearing loss
    û·Â¼Õ½Ç
  • autoimmune disease,t-supperssor function loss
    T-¾ïÁ¦¼¼Æ÷ ±â´É»ó½Ç(¡­åäð¤á¬øàѦÒößÃã÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • signal void
    ¹«½ÅÈ£, ½ÅÈ£¼Ò½Ç, ½ÅÈ£°øÇã
  • SNR [=signal to noise ratio]
    ½ÅÈ£´ëÀâÀ½ºñÀ²
  • vascular signal void
    Ç÷°ü ½ÅÈ£¼Ò½Ç, Ç÷°ü ¹«½ÅÈ£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SI International System of Units [Fr. le Systeme International d'Unites]; sacroiliac; saline infusion; ...
SL sarcolemma; sclerosing leukoencephalopathy; secondary leukemia; segment length; sensation level; sen...
S/N signal/noise [ratio]
SNR selective nerve root [block]; signal-to-noise ratio; substantia nigra zona reticulata; supernumerary...
SRP short rib-polydactyly [syndrome]; signal recognition particle; Society for Radiological Protection; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LORR Loss of Righting Reflex
LOC Loss of consciousness
LOH Loss of constitutional heterozygosity
LOI Loss of imprinting
LRR Loss of righting reflex
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • loss of consciousness
    ÀÇ½Ä »ó½Ç
  • loss of gloss
    ±¤ÅÃÀÇ ¼Ò½Ç
  • loss of molar support
    ±¸Ä¡ºÎ ÁöÁöÀÇ »ó½Ç
  • loss of structural integrity
    ±¸Á¶ÀûÀÎ ¿ÏÀü¼ºÀÇ »ó½Ç
  • patchy loss
    ¹Ý¼º »ó½Ç
  • sensorineural hearing loss
    °¨°¢ ½Å°æ¼º ³­Ã»
  • sensory hearing loss
    °¨°¢¼º ³­Ã»
    ¿Í¿ì
  • weight loss
    üÁß °¨¼Ò
    ´Ü½Ä, ½ÄÀÌÁ¶Àý, º´À¸·Î ÀÎÇØ ³ªÅ¸³ª¸ç, üÁö¹æÀÇ °¨¼Ò ¶Ç´Â À½½Ä¼·Ãë ºÎÁ·À¸·Î ÀÎÇÑ ¿µ¾ç°áÇÌ ½Ã¿¡ ³ªÅ¸³­´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
hearing loss, functional Hearing loss without a physical basis.
(12 Dec 1998)
hearing loss, high-frequency Hearing loss in frequencies above 1000 hertz.
(12 Dec 1998)
hearing loss, noise-induced Hearing loss from exposure to noise. The loss is often in the frequency range 4000-6000 hertz.
(12 Dec 1998)
hearing loss, partial A condition in which the sense of hearing, although defective, is functional with or without a hearing aid. The hearing level for speech is approximately 40-70 decibels I.s.o. (international organization for standardization) or 30-60 db a.s.a. (american standards association).
(12 Dec 1998)
hearing loss, sensorineural Hearing loss resulting from damage to the sensory mechanism internal from the oval and round windows.
(12 Dec 1998)
sensorineural hearing loss <neurology> A form of deafness that occurs due to dysfunction of the auditory nerve (cranial nerve VIII).
(27 Sep 1997)
drift cyclotron loss cone instabilities (DCLC) This is an electrostatic microinstability (frequencies at harmonics of the ion cyclotron frequency) which is of major concern in small mirror devices. Mode is driven by radial gradients in the electron density, and causes loss of ions due to non-conservation of magnetic moment (see adiabatic invariant) as they interact with the mode, and are dispersed in velocity space into the loss cone. Stabilisation is accomplished by increasing the plasma size and by partially filling the loss cone with a continuous extermal warm plasma stream.
(09 Oct 1997)
eddy-current loss <radiobiology> Energy loss due to eddy currents circulating in a resistive material.
(09 Oct 1997)
tooth loss The failure to retain teeth as a result of disease or injury.
(12 Dec 1998)
functional visual loss An apparent loss of visual acuity or visual field with no substantiating physical signs; often due to a natural concern about visual loss combined with suggestibility and a fear of the worst; best treated with reassurance.
(05 Mar 2000)
loss cone In a magnetic mirror machine, particles with a large velocity parallel to the magneitc field and a small velocity perpendicular to the field will be able to escape past the magnetic mirror (see magnetic mirror). In that case the velocity distribution function (see distribution function) will be almost zero in the region of velocity space that allows particles to escape. The shape of that region (in a velocity space diagram with parallel velocity and perpendicular velocity as the axes) is a cone. When a particle undergoes a collision, its velocity gets somewhat randomised. Particles that are scattered into that cone are lost very quickly (in one mirror bounce time). Thus it is called a loss cone. Because of the loss cone, the theoretical maximum particle confinement time of a magnetic mirror machine can be only a few times the particle collision time, this is generally seen as a showstopper for mirror-based fusion research.
(09 Oct 1997)
loss of consciousness Total unresponsiveness. An important neurologic sign.
(27 Sep 1997)
loss of heterozygosity Refers to a mutation that results in the loss of allelic uniqueness, which is often defined as a greater than or equal to 40 percent increase in signal intensity of allelic signal. Loss of heterozygosity is most frequently identified in certain chromosome regions, including 5q, 17p, and 18q.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á